Letters NHS limiting access to high priced drugs

Drug appraisal issues must be resolved at policy level

BMJ 2016; 354 doi: https://doi.org/10.1136/bmj.i4519 (Published 23 August 2016) Cite this as: BMJ 2016;354:i4519
  1. Katharina Kieslich, research associate1,
  2. Peter Littlejohns, professor of public health1,
  3. Albert Weale, emeritus professor of political theory and public policy2
  1. 1King’s College, London, Division of Health and Social Care Research, Addison House, Guy’s Campus, London SE1 1U, UK
  2. 2School of Public Policy, University College London, London WC1H 9QU, UK
  1. katharina.kieslich{at}kcl.ac.uk

Gornall and colleagues’ investigation shows that stakeholders blame NHS England (NHSE) for slow and limited access to new hepatitis C medicines.1 However, NHSE’s tactics reflect a fundamental challenge that the medicines appraisal system in England faces: the new hepatitis C medicines have, in one fell swoop, challenged the cost effectiveness paradigm that is perceived as …

View Full Text

Log in

Log in through your institution


* For online subscription